Sci Tran Med:轻轻一涂病痛走掉,新型水凝胶预防治疗伤口感染两不误

2020-01-14 佚名 生物探索

瑞典隆德大学的研究人员基于人体的天然肽防御系统开发了一种新型水凝胶。它可以预防和治疗伤口感染,杀死多重耐药菌。

意外烧伤、划伤或者手术造成的伤口在愈合过程中总是会受到发炎、感染等问题的困扰,目前针对伤口感染预防和治疗主要的处理手段是对细菌下手,对患者进行抗生素治疗以及施用消毒防腐药。但是抗生素的广泛使用会增加抗生素耐药性的问题。在如今多重耐药菌感染愈发严重的情况下,持续使用抗生素处理伤口并不是长久之计。

瑞典隆德大学的研究人员基于人体的天然肽防御系统开发了一种新型水凝胶。它可以预防和治疗伤口感染,杀死多重耐药菌。这项研究结果于近日发表在《Science Translational Medicine》上。

机体本身就具有治愈伤口的能力,TCP-25是一种凝血酶衍生肽,具有抗菌作用,可清除病原体的脂多糖(造成炎症的罪魁祸首),从而防止与CD14(脂多糖受体)相互作用和Toll样受体二聚化,从而导致下游免疫活化降低。研究人员开发的这种新型水凝胶制剂可通过TCP-25功能化,靶向细菌及其诱导的炎症。

结果表明TCP-25水凝胶可在体外试验及皮下感染的小鼠模型中杀死革兰氏阳性金黄色葡萄球菌和铜绿假单胞菌,水凝胶还可以使脂多糖诱导的局部炎症反应减少。凝胶除了在治疗后24小时内降低炎症反应外,还可在3-4天的时间内进一步降低细菌水平。在猪的伤口模型中,TCP-25预防了金黄色葡萄球菌的感染并降低了促炎细胞因子的浓度。

这款基于机体自然防御机制研发的凝胶目前正处于推动用于烧伤患者的临床研究过程当中。研究人员未来也将致力于开发针对其他器官感染的新型肽基药物,这也为伤口感染的抗生素替代疗法带来了新的希望。

原始出处:

Manoj Puthia, Marta Butrym, Jitka Petrlova, et al. A dual-action peptide-containing hydrogel targets wound infection and inflammation. Science Translational Medicine  01 Jan 2020: Vol. 12, Issue 524, eaax6601, DOI: 10.1126/scitranslmed.aax6601.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1657288, encodeId=29b2165e2886d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 27 11:58:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308071, encodeId=2b1a13080e122, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461049, encodeId=600e1461049d5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538236, encodeId=981f1538236f4, content=<a href='/topic/show?id=498126005f4' target=_blank style='color:#2F92EE;'>#伤口感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26005, encryptionId=498126005f4, topicName=伤口感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a0112946873, createdName=longerg, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610193, encodeId=acaf161019302, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=)]
    2020-04-27 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1657288, encodeId=29b2165e2886d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 27 11:58:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308071, encodeId=2b1a13080e122, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461049, encodeId=600e1461049d5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538236, encodeId=981f1538236f4, content=<a href='/topic/show?id=498126005f4' target=_blank style='color:#2F92EE;'>#伤口感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26005, encryptionId=498126005f4, topicName=伤口感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a0112946873, createdName=longerg, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610193, encodeId=acaf161019302, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=)]
    2020-01-16 tastas
  3. [GetPortalCommentsPageByObjectIdResponse(id=1657288, encodeId=29b2165e2886d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 27 11:58:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308071, encodeId=2b1a13080e122, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461049, encodeId=600e1461049d5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538236, encodeId=981f1538236f4, content=<a href='/topic/show?id=498126005f4' target=_blank style='color:#2F92EE;'>#伤口感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26005, encryptionId=498126005f4, topicName=伤口感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a0112946873, createdName=longerg, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610193, encodeId=acaf161019302, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1657288, encodeId=29b2165e2886d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 27 11:58:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308071, encodeId=2b1a13080e122, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461049, encodeId=600e1461049d5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538236, encodeId=981f1538236f4, content=<a href='/topic/show?id=498126005f4' target=_blank style='color:#2F92EE;'>#伤口感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26005, encryptionId=498126005f4, topicName=伤口感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a0112946873, createdName=longerg, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610193, encodeId=acaf161019302, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1657288, encodeId=29b2165e2886d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 27 11:58:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308071, encodeId=2b1a13080e122, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461049, encodeId=600e1461049d5, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538236, encodeId=981f1538236f4, content=<a href='/topic/show?id=498126005f4' target=_blank style='color:#2F92EE;'>#伤口感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26005, encryptionId=498126005f4, topicName=伤口感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a0112946873, createdName=longerg, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610193, encodeId=acaf161019302, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 16 05:58:00 CST 2020, time=2020-01-16, status=1, ipAttribution=)]

相关资讯

Acta Biomater:新型水凝胶递送RNA干扰分子可有效治疗骨缺损

RNA干扰(RNAi)可能是促进功能组织生长的一种有效和有价值的工具,因为短干扰RNA(siRNA)和微小RNA(miRNA)可以阻断对组织再生具有负面影响的基因的表达。本课题组最近报道了由原位形成的聚乙二醇(PEG)水凝胶的针对头蛋白(siNoggin)和miRNA-20a的siRNA的局部和持续呈递增强了包裹的人骨髓间充质干细胞(hMSC)的成骨分化。本研究中,研究人员介绍了水凝胶体系在大鼠颅

Int J Biol Macromol:新型生物活性丝素蛋白/透明质酸水凝胶的制备及应用

蛋白质和多糖是哺乳动物软组织的主要成分。本研究中,研究人员制备了一种快速水凝胶,通过丝素蛋白(SF)和透明质酸(HA)混合水凝胶模拟天然细胞外基质。 SF/HA水凝胶制备有效,形成时间短。随着HA含量的增加,水凝胶的吸水率、孔隙率和断裂强度增加,而接触角减小显示水凝胶的亲水性极大地提高。特别是,比例为5:5的SF/HA水凝胶具有最高的吸水率和机械性能。复合水凝胶的分子构象主要为无定形结构,并且随着

英国NHS倡导,使用水凝胶降低放射治疗前列腺癌患者的副作用

前列腺癌是男性中最常见的癌症,每年在英格兰新诊断出的病例超过40000例。当足够早地发现前列腺癌时,放射治疗是一种非常有效的治疗方法,高能X射线靶向前列腺,杀死癌细胞并阻止扩散。然而附近的健康器官也会受到影响。SpaceOAR水凝胶充当间隔物,通过临时将其远离治疗中使用的高剂量辐射,减少治疗期间损伤直肠的辐射量。水凝胶作为NHS特定创新计划的一部分得到资助,该计划在过去三年中已经使超过300000

聚丙烯酰胺水凝胶隆乳术后 16 年 乳房罕见畸形一例报告

患者女性,42 岁, 16 年前于某整形美容医院行“双侧乳 房 PAHG 注射隆乳术”,双侧乳房注射量共 350 ml;手术顺 利,术后无明显并发症, 自觉乳房外形满意。6 年前无诱因下 发现双侧乳房增大变形,未做任何处理。

JACC:FDA I期临床试验显示,用于修复心脏的水凝胶可安全注射到人体内

最近的一项研究评估了心肌细胞外基质水凝胶,VentriGel,经心内膜注射,治疗左心室(LV)功能障碍的早期和晚期心肌梗死(MI)患者的安全性和可行性。